Need for Vitamin D in DLBCL

Need for Vitamin D in DLBCL

The effect of vitamin D deficiency (VDD) in elderly patients with diffuse large B-cell lymphoma (DLBCL) was examined. Patients (n…

More...
PET-CT and FL

PET-CT and FL

Findings from a pooled analysis of central scan review in three multicentre studies showed that positron emission tomography/computed tomography (PET-CT)…

More...
CV Risk in HL Survivors

CV Risk in HL Survivors

Adults who had Hodgkin lymphoma (HL) as children are at increased risk of treatment-related cardiovascular (CV) events. In this study,…

More...
Viability of GDP in Lymphoma

Viability of GDP in Lymphoma

This study set out to determine that patients with relapsed or refractory aggressive lymphoma would receive the same benefit from…

More...
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Healthcare Matters

  • 1
  • 2
  • 3
Prev Next

Chemotherapy-free Regimens: An Evolving …

Over the last few years, a number of therapies have received approval for the treatment of lymphomas that are not traditional chemotherapy. One such treatment is“R2”. It stands for Revlimid (lenalidomide) plus Rituxan/MabThera (rituximab). However, it’s not the only one.

Read more

Hope for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCL) are rare and heterogeneous lymphomas comprising numerous histologies. Given the rarity and number of these lymphomas, the tendency has been to group them as one entity. For decades they have been treated in much the same way as B-cell lymphomas using conventional chemotherapy resulting in poor long-term survival.

Read more

A Peek at AIL (Italy)

For the last 20 years, Maria Rita Grattarola has been involved with the Italian Association against leukemia-lymphoma and myeloma (AIL). Prior to joining AIL, Maria Rita was a business teacher. Initially, she volunteered for AIL and over the 20 years Maria Rita has been involved with the organisation, she has worked in many different areas. For the last 10 years, she’s been mostly responsible for organising patient seminars and patient groups.

Read more

Latest Lymphoma News

  • Radiation Therapy and HL

    The use of radiation therapy (RT) has been shown to improve 10-year survival rates in patients with stage I-II Hodgkin’s lymphoma (HL). However, the use of RT in this patient population declined from 56% to 41% between 1998 and 2011. 


    Read more...
  • EU Approves Idelalisib

    Idelalisib has been approved by the European Union for the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). Idelalisib, an oral therapy, is an inhibitor of P13K delta, a protein that is overexpressed in many B-cell malignancies.


    Read more...

What's Happening Around the World

  • A Peek at the IWMF

    This is the second in a series of articles examining the work undertaken by patient organisations to help those affected by WM.

    Waldenstrom’s macroglobulinaemia (WM) is a rare, slow growing blood cancer.

    Read more...  
  • Leukaemia & Blood Cancer New Zealand

    Being a chief executive officer (CEO) comes with many responsibilities as Pru Etcheverry, CEO of Leukaemia & Blood Cancer New Zealand (LBC), can attest. “Every day is different but key responsibilities are income generation and financial management, leadership, brand building and positioning, service delivery for patients and families, and looking at organisational sustainability,” said Pru.

    Read more...  

Research

  • R2CHOP and DLBCL

    This phase II study examined the efficacy of lenalidomide in combination with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R2CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

    Read more...  
  • Improving OS in MCL

    An observational study was undertaken by the Nordic Lymphoma Group to determine the efficacy of different first-line therapies in patients with mantle cell lymphoma (MCL).

    Read more...  

 
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.